Get the Stockscreener App
9.76
10.13%
-1.10
After Hours:
9.63
-0.13
-1.33%
Nurix Therapeutics Inc stock is traded at $9.76, with a volume of 2.00M.
It is down -10.13% in the last 24 hours and up +9.05% over the past month.
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
See More
Previous Close:
$10.86
Open:
$9.71
24h Volume:
2.00M
Relative Volume:
2.09
Market Cap:
$746.15M
Revenue:
$54.55M
Net Income/Loss:
$-193.57M
P/E Ratio:
-3.3772
EPS:
-2.89
Net Cash Flow:
$-181.86M
1W Performance:
+4.05%
1M Performance:
+9.05%
6M Performance:
+10.78%
1Y Performance:
-55.35%
1-Day Range:
$9.50
$10.56
1-Week Range:
$9.43
$10.88
52-Week Range:
$8.18
$29.56
Nurix Therapeutics Inc Stock (NRIX) Company Profile
Name
Nurix Therapeutics Inc
Sector
Industry
Phone
(415) 660-5320
Address
1700 OWENS STREET, SUITE 205, SAN FRANCISCO
Compare NRIX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRIX
Nurix Therapeutics Inc
|
9.76 | 830.24M | 54.55M | -193.57M | -181.86M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Nurix Therapeutics Inc Stock (NRIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-25 | Initiated | Leerink Partners | Market Perform |
| Dec-10-24 | Initiated | BTIG Research | Buy |
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-11-24 | Initiated | Jefferies | Buy |
| Sep-06-24 | Resumed | Robert W. Baird | Outperform |
| Jul-31-24 | Initiated | Truist | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Mar-09-23 | Initiated | Barclays | Overweight |
| Feb-28-23 | Initiated | Oppenheimer | Outperform |
| Oct-11-22 | Initiated | Morgan Stanley | Equal-Weight |
| May-31-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-10-22 | Initiated | Wells Fargo | Equal Weight |
| Dec-29-21 | Initiated | H.C. Wainwright | Buy |
| Oct-14-21 | Initiated | SVB Leerink | Outperform |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Apr-30-21 | Resumed | Piper Sandler | Overweight |
| Apr-30-21 | Initiated | RBC Capital Mkts | Outperform |
| Apr-14-21 | Initiated | Berenberg | Buy |
| Nov-19-20 | Initiated | Robert W. Baird | Outperform |
| Aug-18-20 | Initiated | JP Morgan | Overweight |
| Aug-18-20 | Initiated | Needham | Buy |
| Aug-18-20 | Initiated | Piper Sandler | Overweight |
| Aug-18-20 | Initiated | Stifel | Buy |
View All
Nurix Therapeutics Inc Stock (NRIX) Latest News
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year - simplywall.st
Nurix Therapeutics (NRIX): Losses Worsen 21.7% Annually, Reinforcing Profitability Concerns Despite Growth Narrative - Yahoo Finance
Nurix Therapeutics (NASDAQ:NRIX) Shares Gap Down Following Weak Earnings - MarketBeat
Nurix: Bexobrutideg Advancement Presses Forward With H2 2025 Milestones (NASDAQ:NRIX) - Seeking Alpha
Nurix Therapeutics (NASDAQ:NRIX) Announces Quarterly Earnings Results - MarketBeat
Wall Street Zen Downgrades Nurix Therapeutics (NASDAQ:NRIX) to Strong Sell - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Trading 8.7% HigherStill a Buy? - MarketBeat
Oppenheimer Maintains Nurix Therapeutics (NRIX) Outperform Recommendation - Nasdaq
What analysts say about Nurix Therapeutics Inc stockTake Profit Strategies & Low Cost Portfolio Ideas - earlytimes.in
Nurix Therapeutics (NRIX) Stock Falls After Q3 Earnings Miss - GuruFocus
Using portfolio simulators with Nurix Therapeutics Inc. includedOil Prices & Accurate Technical Buy Alerts - newser.com
Is Nurix Therapeutics Inc. showing signs of accumulationJuly 2025 Breakouts & Long Hold Capital Preservation Plans - newser.com
Nurix Therapeutics (NRIX) Analyst Rating Update: Piper Sandler L - GuruFocus
Detecting price anomalies in Nurix Therapeutics Inc. with AIJuly 2025 Update & Short-Term High Return Ideas - newser.com
Nurix Therapeutics (NRIX) Price Target Lowered by Oppenheimer | - GuruFocus
Nurix Therapeutics (NASDAQ:NRIX) Receives Sell (D-) Rating from Weiss Ratings - MarketBeat
Nurix Therapeutics Posts Downbeat Q3 Results, Joins Orthopediatrics, Levi Strauss And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
Nurix Therapeutics (NRIX) Reports Wider Q3 Earnings Miss - GuruFocus
Levi Strauss, USANA Health Sciences And 3 Stocks To Watch Heading Into Friday - Benzinga
Nurix Therapeutics Inc reports results for the quarter ended August 31Earnings Summary - TradingView
Nurix Therapeutics Reports Third Quarter 2025 Financial Results And Provides A Corporate Update - TradingView
Nurix Therapeutics Doubles Down On Pivotal Trials Despite Losses - Finimize
Nurix Therapeutics, Inc. (NRIX) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
Nurix Therapeutics Inc Reports Q3 2025 Earnings: EPS of ($1.03) Misses Estimates, Revenue at $7.9 Million Falls Short - GuruFocus
NRIX Q3 Revenue Falls Short; Future Research Endeavors Outlined - GuruFocus
Nurix Therapeutics shares tumble 9% on wider-than-expected Q3 loss, revenue miss - Investing.com UK
Nurix Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update - The Manila Times
Earnings Flash (NRIX) Nurix Therapeutics, Inc. Reports Q3 Revenue $7.9M, vs. FactSet Est of $16.0M - MarketScreener
Will Nurix Therapeutics Inc. stock recover faster than peersPortfolio Gains Summary & Growth Focused Entry Point Reports - newser.com
Is Nurix Therapeutics Inc. forming a reversal patternJuly 2025 Outlook & Fast Entry and Exit Trade Plans - newser.com
Using data models to predict Nurix Therapeutics Inc. stock movementJuly 2025 WrapUp & Daily Volume Surge Signals - newser.com
How Nurix Therapeutics Inc. stock performs in weak economyQuarterly Investment Review & High Conviction Investment Ideas - newser.com
Smart tools for monitoring Nurix Therapeutics Inc.’s price action2025 Sector Review & Technical Confirmation Trade Alerts - newser.com
What MACD and RSI say about Nurix Therapeutics Inc.2025 Risk Factors & Safe Swing Trade Setup Alerts - newser.com
Does Nurix Therapeutics Inc. qualify in momentum factor screeningPortfolio Return Report & Real-Time Buy Zone Alerts - newser.com
Nurix Therapeutics Inc Stock Analysis and ForecastGlobal Trade Effects & Low Cost Market Strategies - earlytimes.in
Using Bollinger Bands to evaluate Nurix Therapeutics Inc.2025 Support & Resistance & Low Risk Entry Point Guides - newser.com
Technical analysis overview for Nurix Therapeutics Inc. stockAnalyst Downgrade & Smart Allocation Stock Tips - newser.com
Nurix Therapeutics Inc. stock trend forecastMarket Sentiment Summary & Weekly Momentum Stock Picks - newser.com
What momentum shifts mean for Nurix Therapeutics Inc.Portfolio Return Report & Free Expert Approved Momentum Trade Ideas - newser.com
Nurix Therapeutics Inc.’s volatility index tracking explained2025 Top Gainers & AI Enhanced Execution Alerts - newser.com
Using AI based signals to follow Nurix Therapeutics Inc.Rate Hike & Free Community Supported Trade Ideas - newser.com
What margin trends mean for Nurix Therapeutics Inc. stockJuly 2025 WrapUp & AI Enhanced Trading Signals - newser.com
Nurix Therapeutics (NRIX) Projected to Post Quarterly Earnings on Friday - MarketBeat
Nurix Therapeutics Inc Stock (NRIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Nurix Therapeutics Inc Stock (NRIX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| van Houte Hans | Chief Financial Officer |
Aug 01 '25 |
Sale |
11.03 |
5,402 |
59,598 |
35,512 |
5.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):